Raclopride
From Wikipedia, the free encyclopedia
 |
|
|
Raclopride
|
|
| Systematic (IUPAC) name | |
| 3,5-dichloro-N-[(1-ethylpyrrolidin-2-yl)methyl]- 2-hydroxy-6-methoxy-benzamide |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C15H20Cl2N2O3 |
| Mol. mass | 347.236 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 30 min |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Raclopride is a synthetic compound that acts as an antagonist on D2 dopamine receptors [1] . It can thus be used as a neuroleptic agent to treat schizophrenia. It can be radiolabelled and used in PET scanning to assess the degree of dopamine binding
[edit] References
- ^ Köhler C, Hall H, Ogren SO, Gawell L (1985) Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochemical Pharmacology 34(13):2251-2259.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
